Source: Annual Congress 2002 - Sarcoidosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Baranova, V. Amosov, M. Kameneva, T. Ses, V. Voinov (Saint-Petersburg, Russia). The use of plasmapheresis in the treatment of patients with IY stage of pulmonary sarcoidosis. Eur Respir J 2002; 20: Suppl. 38, 2750

Member's Comments

No comment yet.

Related content which might interest you: The use of symbicort in the treatment of patients with I and II stages of pulmonary sarcoidosis Source: Eur Respir J 2007; 30: Suppl. 51, 85s Year: 2007 The use fluimucil (N-acetylcysteine) in the treatment in patients with III and IY stages of pulmonary sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 713s Year: 2004 The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021 One year follow-up of patients with idiopathic pulmonary fibrosis treated with immunosuppressive therapy Source: Annual Congress 2007 - Considerations in the management of idiopathic pulmonary fibrosis and other interstitial lung diseases Year: 2007 The experience of use plasmaferesis in complex treatment in patients with pulmonary sarcoidosis (PS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Efficacy of different preoperational treatment in patients with destructive pulmonary TB Source: Eur Respir J 2005; 26: Suppl. 49, 688s Year: 2005 The pharmacotherapy options for the intensive treatment phase in patients with primarily diagnosed pulmonary tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012 Safety of corticosteroid therapy in patients with pulmonary sarcoidosis Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 Our clinical experience in surgical therapy of patients with bronchiectasis Source: Eur Respir J 2002; 20: Suppl. 38, 344s Year: 2002 Rituximab in the treatment of refractory pulmonary sarcoidosis Source: Eur Respir J 2014; 43: 1525-1528 Year: 2014 The effectiveness of plasmaferesis in patients with relapsing and progressing course of pulmonary sarcoidosis (5 years follow-up) Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease Year: 2010 The effect of pulmonary rehabilitation programme in patients with pulmonary sarcoidosis Source: Annual Congress 2011 - Rehabilitation, outcome measures and effects Year: 2011 The clinico-immunological evaluation of the ribomunyl therapy in complex treatment of COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 674s Year: 2006 Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009 The efficacy of treatment with surfactant-BL (S-BL) in patients with destructive pulmonary tuberculosis Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis Year: 2007 Markers of resistance to corticosteroids therapy in patients with pulmonary sarcoidosis Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases Year: 2020 Features of intravenous anti TB therapy in patients with first diagnosed pulmonary TB in the intensive phase of treatment Source: International Congress 2017 – MDRTB: detection and management Year: 2017 The clinical value of intravenous pulse therapy in first retreatment pulmonary tuberculosis patients Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 Methotrexate in the treatment of the chronic form of pulmonary and extra - pulmonary sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 712s Year: 2004 Standard therapy for sarcoidosis Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis Year: 2005